Bong-Soo Cha

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7440398/publications.pdf

Version: 2024-02-01

110	3,455	186265	161849
papers	citations	28 h-index	54 g-index

115	115	115	5543
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. Gut and Liver, 2022, 16, 290-299.	2.9	37
2	Renal Tubular Damage Marker, Urinary N-acetyl-Î²-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2022, 46, 104-116.	4.7	5
3	Blood Pressure Levels and Risks of Dementia: a Nationwide Study of 4.5 Million People. Hypertension, 2022, 79, 218-229.	2.7	24
4	Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1976-e1986.	3.6	19
5	Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. JAMA Network Open, 2022, 5, e220262.	5.9	6
6	Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). BMC Medicine, 2022, 20, 93.	5.5	30
7	Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 241-247.	1.3	6
8	Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease. Gut and Liver, 2022, 16, 786-797.	2.9	14
9	Short Term Isocaloric Ketogenic Diet Modulates NLRP3 Inflammasome Via B-hydroxybutyrate and Fibroblast Growth Factor 21. Frontiers in Immunology, 2022, 13, 843520.	4.8	8
10	Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes. Yonsei Medical Journal, 2022, 63, 539.	2.2	0
11	Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway. Diabetes and Metabolism Journal, 2021, 45, 921-932.	4.7	21
12	Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2021, 45, 326-336.	4.7	21
13	Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 1041-1051.	4.4	11
14	Proteinuria as a significant predictive factor for the progression of carotid artery atherosclerosis in non-albuminuric type 2 diabetes. Diabetes Research and Clinical Practice, 2021, 181, 109082.	2.8	2
15	Uric Acid Variability as a Predictive Marker of Newly Developed Cardiovascular Events in Type 2 Diabetes. Frontiers in Cardiovascular Medicine, 2021, 8, 775753.	2.4	9
16	Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes. Diabetes and Metabolism, 2020, 46, 362-369.	2.9	21
17	Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulatingÂhepatic dipeptidyl peptidase-4 expression. Scientific Reports, 2020, 10, 19429.	3.3	9
18	Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 4113-4121.	2.4	5

#	Article	IF	Citations
19	Association Between Serum Bilirubin and the Progression of Carotid Atherosclerosis in Type 2 Diabetes. Journal of Lipid and Atherosclerosis, 2020, 9, 195.	3.5	6
20	Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes. Medicine (United States), 2020, 99, e21038.	1.0	9
21	Efficacy and safety of lobeglitazone versus sitagliptin as an addâ€on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24â€‰weeks. Diabetes, Obesity and Metabolism, 2020, 22, 1869-1873.	4.4	8
22	Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study. Cardiovascular Diabetology, 2020, 19, 81.	6.8	23
23	Comparison of Renal Effects of Ezetimibeâ€“Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis. Journal of Clinical Medicine, 2020, 9, 798.	2.4	4
24	Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. Journal of Clinical Medicine, 2020, 9, 259.	2.4	44
25	Proteinuria Is Associated with Carotid Artery Atherosclerosis in Non-Albuminuric Type 2 Diabetes: A Cross-Sectional Study. Journal of Clinical Medicine, 2020, 9, 136.	2.4	6
26	SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nature Communications, 2020, 11, 2127.	12.8	263
27	Gamma glutamyltransferase and risk of dementia in prediabetes and diabetes. Scientific Reports, 2020, 10, 6800.	3.3	12
28	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. American Journal of Gastroenterology, 2020, 115, 584-595.	0.4	68
29	Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2020, 44, 267.	4.7	28
30	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. Diabetes and Metabolism Journal, 2020, 44, 382.	4.7	46
31	Efficacy and safety of fixedâ€dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, doubleâ€blind, controlled, phase 3 trial. Diabetes, Obesity and Metabolism, 2019, 21, 103-111.	4.4	6
32	Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors. Cancer Chemotherapy and Pharmacology, 2019, 84, 405-414.	2.3	5
33	Glucometabolic characteristics and higher vascular complication risk in Korean patients with type 2 diabetes with non-albumin proteinuria. Journal of Diabetes and Its Complications, 2019, 33, 585-591.	2.3	4
34	The Effectiveness of Intermittent Fasting to Reduce Body Mass Index and Glucose Metabolism: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2019, 8, 1645.	2.4	112
35	Risk of Incident Dementia According to Metabolic Health and Obesity Status in Late Life: A Population-Based Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2942-2952.	3.6	32
36	Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. Diabetes and Metabolism Journal, 2019, 43, 127.	4.7	37

#	Article	IF	Citations
37	Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors. Diabetes and Metabolism Journal, 2019, 43, 158.	4.7	17
38	Cover Image, Volume 21, Issue 4. Diabetes, Obesity and Metabolism, 2019, 21, i.	4.4	0
39	Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. Diabetes and Metabolism Journal, 2019, 43, 31.	4.7	109
40	Spontaneous ketonuria and risk of incident diabetes: a 12Âyear prospective study. Diabetologia, 2019, 62, 779-788.	6.3	11
41	Current Management of Type 2 Diabetes Mellitus in Primary Care Clinics in Korea. Endocrinology and Metabolism, 2019, 34, 282.	3.0	16
42	Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus. Transplantation Proceedings, 2019, 51, 3444-3448.	0.6	3
43	Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and Î²-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis. Diabetes Therapy, 2019, 10, 149-158.	2.5	9
44	Sodiumâ€glucose cotransporter 2 inhibitors regulate ketone body metabolism via interâ€organ crosstalk. Diabetes, Obesity and Metabolism, 2019, 21, 801-811.	4.4	40
45	Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single-Arm, Open-Label, Multi-Center Study. Journal of Korean Medical Science, 2019, 34, e117.	2.5	7
46	Waistâ€toâ€calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1082-1091.	2.8	19
47	Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. Journal of Hepatology, 2018, 68, 764-772.	3.7	86
48	Clinical efficacy of the novel thiazolidinedione lobeglitazone in patients with type 2 diabetes. Diabetes and Metabolism, 2018, 44, 452-455.	2.9	6
49	Relationship Between Circulating Netrin-1 Concentration, Impaired Fasting Glucose, and Newly Diagnosed Type 2 Diabetes. Frontiers in Endocrinology, 2018, 9, 691.	3.5	23
50	Effects of Combination Therapy of Statin and Thiazolidinedione on Vascular Inflammation. Korean Circulation Journal, 2018, 48, 602.	1.9	1
51	Effects of Serum Albumin, Calcium Levels, Cancer Stage and Performance Status on Weight Loss in Parathyroid Hormone-Related Peptide Positive or Negative Patients with Cancer. Endocrinology and Metabolism, 2018, 33, 97.	3.0	5
52	Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus. Frontiers in Endocrinology, 2018, 9, 412.	3.5	26
53	Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis. Endocrinology and Metabolism, 2018, 33, 219.	3.0	18
54	Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study. Scientific Reports, 2018, 8, 11925.	3.3	8

#	Article	IF	Citations
55	Efficacy and safety of ipragliflozin as an addâ€on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2018, 20, 2408-2415.	4.4	30
56	Elevated N -acetyl-Î²- d -glucosaminidase, a urinary tubular damage marker, is a significant predictor of carotid artery atherosclerosis in type 1 diabetes, independent of albuminuria: A cross-sectional study. Journal of Diabetes and Its Complications, 2018, 32, 777-783.	2.3	6
57	The renal tubular damage marker urinary N-acetyl-Î²-d-glucosaminidase may be more closely associated with early detection of atherosclerosis than the glomerular damage marker albuminuria in patients with type 2 diabetes. Cardiovascular Diabetology, 2017, 16, 16.	6.8	25
58	The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study. Diabetes Therapy, 2017, 8, 601-609.	2.5	7
59	Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. Metabolism: Clinical and Experimental, 2017, 66, 23-31.	3.4	55
60	Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. International Journal of Clinical Practice, 2017, 71, e12987.	1.7	4
61	Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition. Autophagy, 2017, 13, 1767-1781.	9.1	152
62	Diabetes self-assessment score and the development of diabetes. Medicine (United States), 2017, 96, e7067.	1.0	2
63	Pre-sarcopenia is associated with renal hyperfiltration independent of obesity or insulin resistance. Medicine (United States), 2017, 96, e7165.	1.0	6
64	Anatomic fat depots and cardiovascular risk: a focus on the leg fat using nationwide surveys (KNHANES 2008â€“2011). Cardiovascular Diabetology, 2017, 16, 54.	6.8	26
65	Impact of diabetes mellitus and chronic liver disease on the incidence of dementia and all-cause mortality among patients with dementia. Medicine (United States), 2017, 96, e8753.	1.0	12
66	Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes. Endocrinology and Metabolism, 2017, 32, 274.	3.0	9
67	Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial. Diabetes and Metabolism Journal, 2017, 41, 135.	4.7	14
68	Morning Spot Urine Glucose-to-Creatinine Ratios Predict Overnight Urinary Glucose Excretion in Patients With Type 2 Diabetes. Annals of Laboratory Medicine, 2017, 37, 9-17.	2.5	5
69	Paroxetine-induced Hypoglycemia in Type 2 Diabetic Patient. The Ewha Medical Journal, 2016, 39, 14.	0.2	1
70	Fellows' perception of fellowship training and overarching issues. Journal of the Korean Medical Association, 2016, 59, 969.	0.3	0
71	Characteristics Predictive for a Successful Switch from Insulin Analogue Therapy to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes. Yonsei Medical Journal, 2016, 57, 1395.	2.2	1
72	Metformin Restores Parkin-Mediated Mitophagy, Suppressed by Cytosolic p53. International Journal of Molecular Sciences, 2016, 17, 122.	4.1	73

#	Article	IF	Citations
73	Comparison and Validation of 10 Equations Including a Novel Method for Estimation of LDL-cholesterol in a 168,212 Asian Population. Medicine (United States), 2016, 95, e3230.	1.0	17
74	Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies. Scientific Reports, 2016, 6, 24013.	3.3	89
75	Reply to â€œThe association between sarcopenia and non-alcoholic fatty liver disease: Potential pitfalls in non-invasive prediction modelsâ€. Journal of Hepatology, 2016, 64, 520-521.	3.7	0
76	Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placeboâ€controlled, doubleâ€blind, multicenter trial. Journal of Diabetes Investigation, 2016, 7, 366-373.	2.4	56
77	Sarcopenia is associated with albuminuria independently of hypertension and diabetes: KNHANES 2008â€“2011. Metabolism: Clinical and Experimental, 2016, 65, 1531-1540.	3.4	46
78	Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. Free Radical Biology and Medicine, 2016, 99, 520-532.	2.9	62
79	Association between dietary acid load and the risk of cardiovascular disease: nationwide surveys (KNHANES 2008â€“2011). Cardiovascular Diabetology, 2016, 15, 122.	6.8	62
80	Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis. Medicine (United States), 2016, 95, e4543.	1.0	13
81	Urinary N-acetyl-Î²-D-glucosaminidase, an early marker of diabetic kidney disease, might reflect glucose excursion in patients with type 2 diabetes. Medicine (United States), 2016, 95, e4114.	1.0	41
82	Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008â€2011). Hepatology, 2016, 63, 776-786.	7.3	261
83	Serum PTHrP Predicts Weight Loss in Cancer Patients Independent of Hypercalcemia, Inflammation, and Tumor Burden. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1207-1214.	3.6	34
84	Association Between Heme Oxygenase-1 Promoter Polymorphisms and the Development of Albuminuria in Type 2 Diabetes. Medicine (United States), 2015, 94, e1825.	1.0	22
85	Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Medicine (United States), 2015, 94, e1103.	1.0	7
86	Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus. Endocrinology and Metabolism, 2015, 30, 84.	3.0	12
87	Glycated Albumin Levels in Patients with Type 2 Diabetes Increase Relative to HbA1cwith Time. BioMed Research International, 2015, 2015, 1-8.	1.9	7
88	Glycated albumin and the risk of micro- and macrovascular complications in subjects with Type 1 Diabetes. Cardiovascular Diabetology, 2015, 14, 53.	6.8	18
89	Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis. Metabolism: Clinical and Experimental, 2015, 64, 1444-1453.	3.4	19
90	Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008â€“2011). Journal of Hepatology, 2015, 63, 486-493.	3.7	264

#	Article	IF	Citations
91	Central obesity is an independent risk factor for microalbuminuria in both the general Korean women and nondiabetic nonhypertensive subpopulation: Association of microalbuminuria and metabolic syndrome from the Korea National Health and Nutrition Examination Survey 2011â€“2012. Clinica Chimica Acta, 2015, 448, 74-79.	1.1	3
92	Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin). Epidemiology and Health, 2015, 37, e2015010.	1.9	5
93	Causal Relationship of Non-alcoholic Fatty Liver Disease with Obesity and Insulin Resistance. Journal of Korean Diabetes, 2014, 15, 76.	0.3	16
94	Lithospermic acid B protects beta-cells from cytokine-induced apoptosis by alleviating apoptotic pathways and activating anti-apoptotic pathways of Nrf2â€“HO-1 and Sirt1. Toxicology and Applied Pharmacology, 2011, 252, 47-54.	2.8	42
95	Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment. Metabolism: Clinical and Experimental, 2011, 60, 165-172.	3.4	14
96	Glycated albumin is a useful glycation index for monitoring fluctuating and poorly controlled type 2 diabetic patients. Acta Diabetologica, 2011, 48, 167-172.	2.5	71
97	Dietary Monounsaturated Fatty Acids but not Saturated Fatty Acids Preserve the Insulin Signaling Pathway via IRSâ€1/PI3K in Rat Skeletal Muscle. Lipids, 2010, 45, 1109-1116.	1.7	37
98	Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle. Life Sciences, 2009, 84, 688-695.	4.3	22
99	Is albuminuria an indicator of myocardial dysfunction in diabetic patients without overt heart disease? A study with Doppler strain and strain rate imaging. Metabolism: Clinical and Experimental, 2008, 57, 448-452.	3.4	23
100	Hyperleptinemia as a Robust Risk Factor of Coronary Artery Disease and Metabolic Syndrome in Type 2 Diabetic Patients. Endocrine Journal, 2008, 55, 1085-1092.	1.6	20
101	A Case of Multiple Endocrine Neoplasia Type 1 Combined with Papillary Thyroid Carcinoma. Yonsei Medical Journal, 2008, 49, 503.	2.2	11
102	The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment. European Journal of Endocrinology, 2007, 157, 167-174.	3.7	15
103	The level of 2-h post-challenge glucose is an independent risk factor of carotid intima-media thickness progression in Korean type 2 diabetic patients. Journal of Diabetes and Its Complications, 2007, 21, 7-12.	2.3	9
104	The long term effects of rosiglitazone on serum lipid concentration and body weight. The Journal of Korean Diabetes Association, 2006, 30, 17.	0.1	0
105	Comparison of the Efficacy and Safety of Glimepiride/Metformin Fixed Combination Versus Free Combination in Patients with Type 2 Diabetes: Multicenter, Randomized, Controlled Trial. The Journal of Korean Diabetes Association, 2006, 30, 466.	0.1	3
106	The Relation between Birth Weight and Insulin Resistance in Korean Adolescents. Yonsei Medical Journal, 2006, 47, 85.	2.2	13
107	Characteristics of Type 2 Diabetes in Terms of Insulin Resistance in Korea. Yonsei Medical Journal, 2005, 46, 484.	2.2	3
108	Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARÎ³ agonists. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E151-E159.	3.5	59

#	Article	IF	Citations
109	Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes. Diabetes Care, 2004, 27, 2654-2660.	8.6	245
110	Free Fatty Acid Metabolism in Human Skeletal Muscle Is Regulated by PPARÎ³ and RXR Agonists. Annals of the New York Academy of Sciences, 2002, 967, 66-70.	3.8	21